Enanta Pharmaceuticals Inc. Stock
The Enanta Pharmaceuticals Inc. stock is trending slightly upwards today, with an increase of €0.10 (0.900%) compared to yesterday's price.
With 9 Buy predictions and not the single Sell prediction the community is currently very high on Enanta Pharmaceuticals Inc..
As a result the target price of 17 € shows a very positive potential of 51.79% compared to the current price of 11.2 € for Enanta Pharmaceuticals Inc..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Enanta Pharmaceuticals Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Enanta Pharmaceuticals Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
B****
Cons
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Enanta Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Enanta Pharmaceuticals Inc. | 0.900% | 0.901% | -11.111% | 73.643% | -17.647% | -33.728% | -68.000% |
| Evolus Inc | -0.040% | -0.496% | -14.130% | -33.154% | -4.330% | -42.703% | -41.085% |
| Heron Therapeutics Inc. | -1.990% | 2.964% | 15.558% | -71.508% | -61.329% | -69.229% | -95.846% |
| Rhythm Pharmaceuticals | -1.080% | 1.667% | -5.181% | 26.207% | -2.139% | 479.114% | 535.417% |
Comments
Enanta Pharmaceuticals (ENTA) had its "buy" rating reaffirmed by HC Wainwright. They now have a $20.00 price target on the stock.
Show more
Ratings data for ENTA provided by MarketBeat
Enanta Pharmaceuticals (ENTA) is now covered by Rodman & Renshaw. They set a "buy" rating and a $20.00 price target on the stock.
Show more
Ratings data for ENTA provided by MarketBeat
Enanta Pharmaceuticals (NASDAQ:ENTA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Show more
Ratings data for ENTA provided by MarketBeat